CD274 and esophageal squamous cell carcinoma: In the KEYNOTE 590 study, pembrolizumab plus chemotherapy was superior to placebo plus chemotherapy for OS in patients with esophageal squamous cell carcinoma (SCC) and PD-L1 CPS of 10 or more (median 13.9 months vs. 8.8 months; HR 0.57 95% CI 0.43–0.75; p < 0.0001) and in all randomized patients (12.4 months vs. 9.8 months; HR 0.73 95% CI 0.62–0.86 p < 0.0001).